Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 2006, p. 1768-1772, Vol. 50, No. 5
0066-4804/06/$08.00+0 doi:10.1128/AAC.50.5.1768-1772.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Unité de Biologie des infections virales émergentes, Institut Pasteur, Laboratoire P4, Jean Mérieux Inserm, Institut Fédératif de Recherche 128-Biosciences Lyon Gerland, 21 Avenue Tony Garnier, 69365 Lyon, France,1 Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium2
Received 13 September 2005/ Returned for modification 8 December 2005/ Accepted 15 February 2006
Clinical nonrandomized trials demonstrate some efficacy for ribavirin in the treatment of patients with severe Nipah virus-induced encephalitis. We report here that EICAR, the 5-ethynyl analogue of ribavirin, and the OMP-decarboxylase inhibitors 6-aza-uridine and pyrazofurin have strong antiviral activity against Nipah virus replication in vitro. Ribavirin and 6-aza-uridine were tested further in hamsters infected with a lethal dose of Nipah virus. The activity of these small-molecule inhibitors was compared with that of the interferon inducer poly(I)-poly(C12U). Both ribavirin and 6-aza-uridine were able to delay but not prevent Nipah virus-induced mortality. Poly(I)-poly(C12U), at 3 mg/kg of body weight daily from the day of infection to 10 days postinfection, prevented mortality in 5 of 6 infected animals.
Present address: Institut Pasteur of Shanghai, Chinese Academy of Sciences, 225 South Chongqin Road, 200025 Shanghai, People's Republic of China.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»